TiGenix announces the clinical development of Cx611 in early rheumatoid arthritis and severe sepsis

"Having considered the demonstrated therapeutic effects of allogeneic stem cells, the animal and clinical data for Cx611 collected so far, the potential applications into areas of high unmet medical need, and the advice from clinical experts in Europe and in the United States, we are convinced that it is in early rheumatoid arthritis and in severe ... (more)

http://ift.tt/1nW3tse